Frontlight ResearchEarly access
Gaucher disease trials in France
1 of 2 trials · From ClinicalTrials.gov, checked 17 November 2026. Ask the study team whether a trial fits you.
- Phase 2/3Not yet taking people in FranceLong-Term Safety and Tolerability of Nizubaglustat in Participants With Rare Lysosomal Disorders
- Where
- Paris
- Age
- 4 years to 64 years
- People
- 218
- Run by
- Azafaros B.V.
See details and how to joinNCT07885917 · EU 2026-527156-12-00